Παρακολούθηση
Ryan D Morrison
Ryan D Morrison
Inotiv
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα inotivco.com
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice
K Kaufmann, I Romaine, E Days, C Pascual, A Malik, L Yang, B Zou, Y Du, ...
ACS chemical neuroscience 4 (9), 1278-1286, 2013
1592013
Metabolism and distribution of clozapine-N-oxide: implications for nonhuman primate chemogenetics
J Raper, RD Morrison, JS Daniels, L Howell, J Bachevalier, T Wichmann, ...
ACS chemical neuroscience 8 (7), 1570-1576, 2017
1242017
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models
GJ Digby, MJ Noetzel, M Bubser, TJ Utley, AG Walker, NE Byun, ...
Journal of Neuroscience 32 (25), 8532-8544, 2012
1202012
The discovery and characterization of ML218: a novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson’s …
Z Xiang, AD Thompson, JT Brogan, ML Schulte, BJ Melancon, D Mi, ...
ACS chemical neuroscience 2 (12), 730-742, 2011
1182011
Design, Synthesis, and Biological Evaluation of Halogenated N-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an Isoform …
RR Lavieri, SA Scott, PE Selvy, K Kim, S Jadhav, RD Morrison, JS Daniels, ...
Journal of medicinal chemistry 53 (18), 6706-6719, 2010
1002010
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in …
CK Jones, M Bubser, AD Thompson, JW Dickerson, N Turle-Lorenzo, ...
Journal of Pharmacology and Experimental Therapeutics 340 (2), 404-421, 2012
982012
Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: development of a highly selective and more potent in vitro probe
E Delpire, A Baranczak, AG Waterson, K Kim, N Kett, RD Morrison, ...
Bioorganic & medicinal chemistry letters 22 (14), 4532-4535, 2012
952012
Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu3 Selective and CNS Penetrant Negative …
CJ Wenthur, R Morrison, AS Felts, KA Smith, JL Engers, FW Byers, ...
Journal of medicinal chemistry 56 (12), 5208-5212, 2013
892013
Potentiation of M 1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model
A Ghoshal, JM Rook, JW Dickerson, GN Roop, RD Morrison, ...
Neuropsychopharmacology 41 (2), 598-610, 2016
772016
Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents
JL Engers, AL Rodriguez, LC Konkol, RD Morrison, AD Thompson, ...
Journal of medicinal chemistry 58 (18), 7485-7500, 2015
702015
Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1, 3, 8-Triazaspiro [4.5] decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in …
MC O’Reilly, SA Scott, KA Brown, TH Oguin III, PG Thomas, JS Daniels, ...
Journal of medicinal chemistry 56 (6), 2695-2699, 2013
682013
Discovery, Synthesis, and Structure–Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182 …
CK Jones, DW Engers, AD Thompson, JR Field, AL Blobaum, ...
Journal of medicinal chemistry 54 (21), 7639-7647, 2011
662011
Chemical Modulation of Mutant mGlu1 Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics
HP Cho, PM Garcia-Barrantes, JT Brogan, CR Hopkins, CM Niswender, ...
ACS chemical biology 9 (10), 2334-2346, 2014
542014
Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor …
TM Bridges, JM Rook, MJ Noetzel, RD Morrison, Y Zhou, RD Gogliotti, ...
Drug Metabolism and Disposition 41 (9), 1703-1714, 2013
472013
Targeting selective activation of M1 for the treatment of Alzheimer’s disease: further chemical optimization and pharmacological characterization of the M1 positive allosteric …
JC Tarr, ML Turlington, PR Reid, TJ Utley, DJ Sheffler, HP Cho, R Klar, ...
ACS chemical neuroscience 3 (11), 884-895, 2012
452012
Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs
JL Engers, KA Bollinger, RL Weiner, AL Rodriguez, MF Long, MM Breiner, ...
ACS medicinal chemistry letters 8 (9), 925-930, 2017
412017
The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5
RD Morrison, AL Blobaum, FW Byers, TS Santomango, TM Bridges, ...
Drug Metabolism and Disposition 40 (9), 1834-1845, 2012
412012
Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM
DJ Sheffler, CJ Wenthur, JA Bruner, SJS Carrington, PN Vinson, KK Gogi, ...
Bioorganic & medicinal chemistry letters 22 (12), 3921-3925, 2012
412012
Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator …
DW Engers, AL Blobaum, RD Gogliotti, YY Cheung, JM Salovich, ...
ACS chemical neuroscience 7 (9), 1192-1200, 2016
392016
Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS …
LC Morris, KD Nance, PR Gentry, EL Days, CD Weaver, CM Niswender, ...
Journal of medicinal chemistry 57 (23), 10192-10197, 2014
382014
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–20